Company profile
Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OBEXELIMAB | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05662241 | phase3 | active_not_recruiting | 2023-01-09 | 2025-11-13 | Zenas BioPharma (USA), LLC | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease |
| NCT05794516 | phase1 | completed | 2023-06-19 | 2024-03-21 | Zenas BioPharma (USA), LLC | A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants |
| NCT05542303 | phase1 | completed | 2022-10-16 | 2023-04-04 | Zenas BioPharma (USA), LLC | A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects |
| NCT06564311 | phase2 | active_not_recruiting | 2024-08-26 | 2025-08-28 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) |
| NCT06559163 | phase2 | active_not_recruiting | 2024-09-17 | 2026-09-01 | Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus |
FDA applications (0)
No records yet.